6 citations
,
September 2020 in “Journal of The American Academy of Dermatology” This letter discusses how severe baldness in men is associated with higher risk of severe COVID-19, and highlights research suggesting antiandrogen medications may improve outcomes.
April 2022 in “Brazilian Medical Students” This review synthesizes existing evidence on the link between androgenic alopecia and severe COVID-19 outcomes, noting a potential role for anti-androgenic therapies in treating SARS-CoV-2 infections.
176 citations
,
May 2020 in “Dermatologic Therapy” This review discusses the cutaneous symptoms associated with COVID-19 and their potential use in diagnosing and assessing the severity of the disease, but it reports no new clinical results.
121 citations
,
November 2020 in “Endocrine” This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.
January 2022 in “International Journal of Science and Research (IJSR)” This review discusses the biochemical and psychological impacts of polycystic ovary syndrome on immune functions against COVID-19 but reports no new clinical results.